Victory Capital Holdings (VCTR - Free Report) has announced assets under management (AUM) by its subsidiaries of $146.8 billion for October 2019. Results display a nearly 1% rise from $145.8 billion recorded as of Sep 30, 2019.
At the end of October, Victory Capital’s U.S. Mid Cap Equity AUM decreased slightly from September-end to $25.4 billion. However, U.S. Small Cap Equity and Global / Non-U.S. Equity climbed 1.1% and 3%, respectively. Further, U.S. Large Cap Equity AUM increased slightly from September to $13.5 billion.
However, Fixed Income assets were $37.8 billion, almost stable sequentially. Nevertheless, Victory Capital recorded $30.2 billion in Solutions, which was up 2.1% from $29.6 billion reported in September.
Other assets were down 10.7% to $217 million. Money Market Assets were $11.5 billion, almost stable on a sequential basis.
Sound positioning of Victory Capital’s integrated multi-boutique business model in a rapidly evolving industry and the effectiveness of its distribution platform might keep supporting the company’s performance.
Shares of the company have gained 15.6% over the past six months against 4% decline recorded by the industry.
Currently, Victory Capital carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Franklin Resources (BEN - Free Report) announced preliminary AUM by its subsidiaries of $693.1 billion for October 2019. Results display marginal increase from the $692.6 billion recorded as of Sep 30, 2019. Slight net outflows were offset by net market gains. Further, the reported figure inched up 1.5% year on year.
Cohen & Steers (CNS - Free Report) reported preliminary AUM of $72 billion as of Oct 31, 2019, up 1.6% from the prior-month level. Market appreciation of $967 million and net inflows of $333 million were partly offset by distributions of $186 million.
Invesco’s (IVZ - Free Report) preliminary October-end AUM of $1,195.2 billion inched up 0.9% from the prior month. This upswing stemmed from favorable market returns, and reinvested distributions. Also, favorable foreign-exchange movement boosted the month’s AUM by $5 billion. These were partly offset by outflows in long-term AUM, money market, and non-management fee earning AUM.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>